UpdatesPress Release
Alembic Pharma reported strong Q1 results.
Alembic Pharmaceuticals LimitedAPLLTD · Filed with the exchange
Revenue rose 26% to Rs 2150 Cr, PAT up 12% to Rs 173 Cr.
EBITDA margin at 24%. US Formulation surged 49% with 7 launches, India Branded grew 7% (3 new products), and API business was up 33%. Received 10 ANDA approvals.
No comments yet. Be the first.